查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1466028

Castleman氏病治療市場：按疾病類型、適應症、治療方法和應用分類 - 全球預測 2024-2030

Castleman Disease Treatment Market by Disease Type, Indication, Treatment, Application - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

Castleman氏病治療市場規模預計2023年為2.9433億美元，2024年達到3.3415億美元，預計2030年將達到7.1987億美元，複合年成長率為13.62%。

Castleman氏病的治療涉及專門的醫療治療，以治療一種稱為Castleman氏病的罕見疾病。此疾病的特徵是身體淋巴結中細胞過度生長，引起從發燒、疲勞到異常體重減輕等症狀。近年來，包括Castleman氏病在內的罕見疾病的盛行率增加，因此需要增加治療選擇。多年來，我們對Castleman氏病的了解不斷加深，從而促進了標靶治療的發展。正在進行的研究重點是識別生物標記、了解潛在的病理學和發現新的治療方法。Castleman氏病的幾種治療方法已獲得孤兒藥資格，這為製藥公司開發罕見疾病的治療方法提供了獎勵。然而，藥物開發成本高昂、治療選擇有限以及嚴格的監管合規性阻礙了治療的擴展。醫療保健專業人員、研究人員和倡導團體正在全球範圍內合作，以改善Castleman氏病的診斷、管理和治療。

主要市場統計
基準年[2023] 2.9433億美元
預測年份 [2024] 33415萬美元
預測年份 [2030] 71987萬美元
複合年成長率（%） 13.62%

疾病類型：多中心Castleman氏病有可能導致全身器官衰竭，需要快速制定治療策略。

多中心Castleman氏病(MCD) 是一種導致患者身體多個區域淋巴結腫大的疾病。多中心Castleman氏病有三種症狀：多發性神經炎、器官腫大、內分泌疾病、M蛋白、皮膚改變(POEMS)相關的MCD、人類皰疹病毒8(HHV-8)相關的MCD和特發性MCD 。多中心Castleman氏病的治療通常涉及藥物和其他治療方法來抑制細胞過度生長。特定治療方法還取決於疾病的嚴重程度以及患者感染疾病感染疾病人類免疫力缺乏病毒 (HIV)、人類皰疹病毒 8 (HHV-8) 或兩者。單中心Castleman氏病(UCD) 是一種影響一個淋巴結的疾病，通常位於胸部或腹部。單中心Castleman氏病可以透過手術切除受影響的淋巴結來治療。

增加血管瘤肝血管瘤淋巴結病例的Castleman氏病治療選擇

肝血管瘤瘤樣淋巴結增生與長期發燒、貧血、體重減輕、脾腫大和高丙種球蛋白血症有關。肝血管瘤淋巴球錯構瘤或假性淋巴瘤最常見於乳房，常被誤認為是伴隨淋巴瘤樣組織的胸腺腫瘤。這是一種罕見的疾病，經常使用免疫調節療法。 Castleman 腫瘤是一種罕見的縱膈淋巴結增生，類似胸腺瘤。典型的組織學特徵包括結節中淋巴球的洋蔥皮樣排列和具有明顯毛細血管增殖的異常脈管系統。巨大良性淋巴瘤是發生在大腸中最常見的非上皮性良性腫瘤。通常在直腸中觀察到單一圓形息肉，呈紅紫色或灰色，直徑從幾毫米到 3 至 4 公分不等。巨大淋巴結增生是一種病因不明的非腫瘤性淋巴增生性疾病，通常發生在胸部。這種疾病的型態辨識是基於各種組織學特徵的組合。淋巴結血管肌瘤性錯構瘤（AMH-LN）是指平滑肌、血管、膠體基質和脂肪細胞的異常良性增生。

治療方法化療的進步正在增加Castleman氏病治療方案的採用。

抗病毒藥物用於針對有害病毒。抗病毒藥物用於緩解疾病症狀。化療是指使用藥物和化療來殺死患者體內快速生長的癌細胞。低劑量單藥化療，例如每日口服Etoposide或間歇性Etoposide或長春花鹼，已用於治療 MCD。皮質類固醇是一種強效發炎藥，可以緩解疾病症狀。全身給予皮質類固醇可以緩解症狀，但不能預測腫瘤縮小。免疫療法利用人體的自​​然防禦來對抗疾病。單株抗體是實驗室製造的蛋白質，僅與一種致病抗原結合。利Rituximab治療對 HHV-8 相關 MCD 非常有效。有些 HIV 感染者需要接受Rituximab抗逆轉錄病毒治療 (ART)。放射線治療是一種利用放射線殺死癌細胞並縮小腫瘤的癌症治療方法。對於單中心Castleman氏病，放射線治療是一種有效的治療選擇，且反應率較高。

門診手術中心是提供最佳患者照護的首選

門診手術中心 (ASC) 是一個現代化的醫療設施，旨在提供當天的手術治療，包括診斷和預防程序。這些中心由於醫療效率高並且減少了治療預約的等待時間，在Castleman氏病的治療中越來越普及。由於疾病管理的複雜性與護理強度有關，醫院部門仍然是Castleman氏病治療的主要貢獻者。

區域洞察

美洲，特別是美國和加拿大，擁有相對完善的診斷和治療罕見疾病（包括Castleman氏病）的基礎設施。有專門研究Castleman氏病的專門醫療中心和專家，患者倡導團體和研究組織為提高診斷和治療的認知和進步做出了貢獻。儘管與其他地區相比，亞洲Castleman氏病的治療機會有限，但政府對醫療保健發展的投資極大地推動了針對這種罕見疾病的更有針對性的治療方法。該地區的主要城市提供先進的診斷和治療方案，而規模較小的學術機構正在中國、日本和印度大力投資研發活動。在歐洲，各國政府正在促進相關人員在醫療保健和研究工作方面的合作，以幫助治療Castleman氏病。歐洲藥品管理局正在努力審查和核准改進的藥物，以改善該地區Castleman氏病者的治療提供和獲得機會。

FPNV定位矩陣

FPNV 定位矩陣對於評估Castleman氏病治療市場至關重要。我們檢視與業務策略和產品滿意度相關的關鍵指標，以對供應商進行全面評估。這種深入的分析使用戶能夠根據自己的要求做出明智的決策。根據評估，供應商被分為四個成功程度不同的像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市場佔有率分析

市場佔有率分析是一種綜合工具，可以對Castleman氏病治療市場中供應商的現狀進行深入而深入的研究。全面比較和分析供應商在整體收益、基本客群和其他關鍵指標方面的貢獻，以便更好地了解公司的績效及其在爭奪市場佔有率時面臨的挑戰。此外，該分析還提供了對該行業競爭特徵的寶貴見解，包括在研究基準年觀察到的累積、分散主導地位和合併特徵等因素。詳細程度的提高使供應商能夠做出更明智的決策並制定有效的策略，從而在市場上獲得競爭優勢。

本報告在以下方面提供了寶貴的見解：

1. 市場滲透率：提供有關主要企業所服務的市場的全面資訊。

2. 市場開拓：我們深入研究利潤豐厚的新興市場，並分析其在成熟細分市場的滲透率。

3. 市場多元化：提供有關新產品發布、開拓地區、最新發展和投資的詳細資訊。

4. 競爭評估和情報：對主要企業的市場佔有率、策略、產品、認證、監管狀況、專利狀況和製造能力進行全面評估。

5. 產品開發與創新：提供對未來技術、研發活動和突破性產品開發的見解。

本報告解決了以下關鍵問題：

1.CastlemanCastleman氏病治療市場的市場規模與預測為何？

Castleman氏病治療市場預測期間需要考慮投資的產品、細分市場、應用和領域有哪些？

3.CastlemanCastleman氏病治療市場的技術趨勢和法規結構是什麼？

4.CastlemanCastleman氏病治療市場主要廠商的市場佔有率是多少？

5. 進入Castleman氏病治療市場的合適型態和策略手段是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • Castleman氏病的盛行率和有效疾病管理的必要性
      • 為Castleman氏病治療提供孤兒藥指定和核准
      • 患者支持團體的興起和卡斯爾曼治療的意識計劃
    • 抑制因素
      • Castleman氏病藥物開發的複雜性
    • 機會
      • 新Castleman氏病治療方法的開發不斷取得進展
      • Castleman氏病個人化醫療新趨勢
    • 任務
      • 缺乏標準化的治療通訊協定
  • 市場區隔分析
    • 疾病類型：由於潛在的全身器官衰竭，需要快速開發多中心Castleman氏病的治療策略
    • 適應症：越來越多採用Castleman氏病治療肝血管瘤淋巴瘤病例
    • 治療：化療的進步擴大了Castleman氏病治療方案的採用
    • 用途：透過提供最佳的患者照護來優先考慮門診手術中心
  • 市場擾動分析
  • 波特五力分析
  • 價值鍊和關鍵路徑分析
  • 價格分析
  • 技術分析
  • 專利分析
  • 貿易分析
  • 法規結構分析

第6章Castleman氏病治療市場：依疾病類型

  • 多中心Castleman氏病
  • 單中心Castleman氏病

第7章Castleman氏病治療市場（按適應症）

  • 血管濾泡淋巴結增生
  • 肝血管瘤管
  • 卡斯特曼瘤
  • 巨大良性淋巴瘤
  • 巨大淋巴結增生
  • 淋巴錯構瘤

第8章Castleman氏病治療市場（依治療）

  • 抗病毒藥物
  • 化療
  • 皮質類固醇
  • 免疫療法
  • 單株抗體
  • 放射治療

第9章Castleman氏病治療市場：依應用分類

  • 門診手術中心
  • 醫院

第10章 美洲Castleman氏病治療市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章亞太Castleman氏病治療市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章歐洲、中東和非洲Castleman氏病治療市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭場景分析
    • FDA核准托珠單抗生物相似藥 Tofidence
    • 中外製藥Actemra的額外適應症在日本獲得核准，用於治療與癌症治療相關的細胞激素釋放症候群
    • Medable 與 Every Cure 合作，加速罕見疾病治療方法的發現
  • 戰略分析和建議

第14章競爭產品組合

  • 主要企業簡介
  • 主要產品系列
Product Code: MRR-4312A385A340

[196 Pages Report] The Castleman Disease Treatment Market size was estimated at USD 294.33 million in 2023 and expected to reach USD 334.15 million in 2024, at a CAGR 13.62% to reach USD 719.87 million by 2030.

Castleman disease treatment involves a specialized healthcare procedure to manage a rare illness called Castleman disease, which is characterized by the overgrowth of cells in the body's lymph nodes, causing a variety of symptoms from fever and fatigue to abnormal weight loss. Recent years have observed an increased prevalence of rare diseases, including Castleman disease, necessitating enhanced treatment options. The understanding of Castleman disease has advanced over the years, leading to the development of targeted therapies. Ongoing research focuses on identifying biomarkers, understanding the underlying pathophysiology, and discovering novel treatment options. Some treatments for Castleman disease have received orphan drug designation, which provides incentives for pharmaceutical companies to develop therapies for rare diseases. However, the high cost of drug development, limited treatment options, and strict regulatory compliance impede the expansion of treatment. Healthcare professionals, researchers, and advocacy groups are collaborating on a global scale to improve the diagnosis, management, and treatment of Castleman disease.

KEY MARKET STATISTICS
Base Year [2023] USD 294.33 million
Estimated Year [2024] USD 334.15 million
Forecast Year [2030] USD 719.87 million
CAGR (%) 13.62%

Disease type: Need for rapid deployment of treatment strategies for multicentric Castleman's disease due to the chances of systemic organ failure

Multicentric Castleman's disease (MCD) refers to the disease condition that causes lymph node enlargement in multiple regions of the patient's body. There are three categories of MCD-Polyneuropathy, organomegaly, endocrinopathy, M proteins, and skin changes (POEMS)-associated MCD, human herpesvirus-8 (HHV-8)-associated MCD, and idiopathic MCD. Treatment for multicentric Castleman disease generally involves medicines and other therapies to control cell overgrowth. Specific treatment may also depend on the extent of the disease and whether the patient has human immunodeficiency virus infection (HIV), human herpesvirus-8 (HHV-8) infection, or both. Unicentric Castleman's disease (UCD) refers to a disorder that affects a single lymph node in the patient's body, usually in the chest or abdomen. Unicentric Castleman disease can be treated by surgically removing the diseased lymph node.

Indication: Rising adoption of Castlemann's disease treatment options for tackling angiomatous lymphoid cases

Angiofollicular lymph node hyperplasia is associated with prolonged fever, anemia, weight loss, splenomegaly, and hypergammaglobulinemia. Angiomatous lymphoid hamartomas or pseudolymphomas have been reported most commonly within the chest and are usually mistaken for thymic tumors of lymphomatous tissue. It is a rare manifestation where immunomodulatory treatment is often utilized. Castleman tumor is an unusual mediastinal lymph node hyperplasia that resembles thymoma. The characteristic histologic characteristics include an onion skin arrangement of the lymphocytes in nodules and an unusual vasculature with marked capillary proliferation. Giant benign lymphoma is the most common non-epithelial benign tumor occurring in the large intestine. It is usually observed in the rectum as a single reddish-purple or grey, rounded polyp varying in diameter from a few millimeters to 3-4 centimeters. Giant lymph node hyperplasia is a nonneoplastic lymphoproliferative disorder of unknown etiology that is usually observed in the chest. The morphological recognition of this disease is based on a combination of various histological features. Angiomyomatous hamartoma of lymph nodes (AMH-LN) refers to an unusual benign proliferation of smooth muscle, blood vessels, collagenous stroma, and adipocytes.

Treatment: Advancements in chemotherapy treatments leading to expanding adoption of Castleman disease treatment options

Antiviral medications are used to target harmful viruses. The antiviral drugs are used to ease disease symptoms. Chemotherapy refers to the practice of utilizing a drug or chemical treatment to kill fast-growing cancer cells in a patient's body. Low-dose single-agent chemotherapy treatment options, such as daily oral etoposide59 or intermittent etoposide or vinblastine, have been utilized for MCD. Corticosteroids are powerful anti-inflammatory drugs that can mitigate disease symptoms. Systemic corticosteroids can provide symptomatic relief but do not predictably reduce tumor size. Immunotherapy takes advantage of the body's natural defenses to fight the disease. Monoclonal antibodies refer to proteins made in a laboratory that bind to one pathogenic antigen only. In HHV-8-associated MCD, treatment with rituximab is highly effective. For some patients with HIV infection, antiretroviral therapy (ART) should be included with the rituximab. Radiation therapy refers to a cancer treatment that uses bursts of radiation to target and kill cancer cells and shrink tumors. In unicentric Castleman disease, radiotherapy radiation therapy is a viable treatment option because of its high response rates.

Application: Preference for ambulatory surgical centers due to provision of optimum patient care

Ambulatory surgical centers (ASCs) refer to modern medical facilities that aim to provide same-day surgical care, including diagnostic and preventive procedures. These centers have gradually become popular for the treatment of Castleman disease due to their perceived medical efficiency and the reduced waiting times involved in scheduling a treatment. The hospital segment continues to remain a significant contributor to Castleman disease treatment owing to the intensity of care that comes with the complex nature of disease management.

Regional Insights

The Americas, particularly the U.S. and Canada, has a relatively well-established infrastructure for rare disease diagnosis and treatment, including Castleman disease. There are specialized medical centers and experts focused on the condition, and patient advocacy groups and research institutes have contributed to the awareness and advancements in diagnosis and treatment. In Asia, access to castle treatment is limited when compared to the other regions; however, the government investment in healthcare development has significantly strived toward a more focused approach to rare diseases. Major cities in the region offer advanced diagnostic and treatment options, and small-scale academic institutes in China, Japan, and India are investing heavily in R&D activities. In Europe, the government promotes stakeholder cooperation in healthcare and research activities, benefiting the treatment of Castleman disease. The European Medicines Agency has been working on reviewing improved medications and approving them to elevate the provision and access to Castleman treatment to patients in the region.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Castleman Disease Treatment Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Castleman Disease Treatment Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Castleman Disease Treatment Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Agilent Technologies, Inc., Amgen Inc., Artiva Biotherapeutics, Inc., Bayer AG, Bio-Rad Laboratories, Inc., Biogen Inc., Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Cadila Pharmaceuticals Limited, Celltrion Healthcare Co.,Ltd., F. Hoffmann-La Roche AG, Gilead Sciences, Inc., GlaxoSmithKline PLC, Glenmark Pharmaceuticals S.A., Johnson & Johnson Services, Inc., LGM Pharma, Merck & Co., Inc., Novartis AG, Octapharma AG, Pfizer, Inc., Recordati Group Company, Recordati S.p.A., Sanofi S.A., Sartorius AG, Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Thermo Fisher Scientific Inc., and Viatris Inc..

Market Segmentation & Coverage

This research report categorizes the Castleman Disease Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Disease Type
    • Multicentric Castleman's Disease
    • Unicentric Castleman's Disease
  • Indication
    • Angiofollicular Lymph Node Hyperplasia
    • Angiomatous Lymphoid
    • Castleman Tumor
    • Giant Benign Lymphoma
    • Giant Lymph Node Hyperplasia
    • Hamartoma of the Lyphatics
  • Treatment
    • Antiviral Drugs
    • Chemotherapy
    • Corticosteroids
    • Immunotherapy
    • Monoclonal Antibodies
    • Radiation Therapy
  • Application
    • Ambulatory Surgical Centers
    • Hospitals
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Castleman Disease Treatment Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Castleman Disease Treatment Market?

3. What are the technology trends and regulatory frameworks in the Castleman Disease Treatment Market?

4. What is the market share of the leading vendors in the Castleman Disease Treatment Market?

5. Which modes and strategic moves are suitable for entering the Castleman Disease Treatment Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Prevalence of Castleman disease and the need for effective disease management
      • 5.1.1.2. Provision of orphan drug designation and approvals for Castleman disease treatments
      • 5.1.1.3. Rise of patient advocacy groups and awareness programs for Castleman treatment
    • 5.1.2. Restraints
      • 5.1.2.1. Complexities in the drug development for Castleman disease
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing advancements in the development of new Castleman disease treatment
      • 5.1.3.2. Emerging trend of personalized medicine for Castleman disease treatment
    • 5.1.4. Challenges
      • 5.1.4.1. Lack fo standardized treatment protocols
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Disease type: Need for rapid deployment of treatment strategies for multicentric Castleman's disease due to the chances of systemic organ failure
    • 5.2.2. Indication: Rising adoption of Castlemann's disease treatment options for tackling angiomatous lymphoid cases
    • 5.2.3. Treatment: Advancements in chemotherapy treatments leading to expanding adoption of Castleman disease treatment options
    • 5.2.4. Application: Preference for ambulatory surgical centers due to provision of optimum patient care
  • 5.3. Market Disruption Analysis
  • 5.4. Porter's Five Forces Analysis
    • 5.4.1. Threat of New Entrants
    • 5.4.2. Threat of Substitutes
    • 5.4.3. Bargaining Power of Customers
    • 5.4.4. Bargaining Power of Suppliers
    • 5.4.5. Industry Rivalry
  • 5.5. Value Chain & Critical Path Analysis
  • 5.6. Pricing Analysis
  • 5.7. Technology Analysis
  • 5.8. Patent Analysis
  • 5.9. Trade Analysis
  • 5.10. Regulatory Framework Analysis

6. Castleman Disease Treatment Market, by Disease Type

  • 6.1. Introduction
  • 6.2. Multicentric Castleman's Disease
  • 6.3. Unicentric Castleman's Disease

7. Castleman Disease Treatment Market, by Indication

  • 7.1. Introduction
  • 7.2. Angiofollicular Lymph Node Hyperplasia
  • 7.3. Angiomatous Lymphoid
  • 7.4. Castleman Tumor
  • 7.5. Giant Benign Lymphoma
  • 7.6. Giant Lymph Node Hyperplasia
  • 7.7. Hamartoma of the Lyphatics

8. Castleman Disease Treatment Market, by Treatment

  • 8.1. Introduction
  • 8.2. Antiviral Drugs
  • 8.3. Chemotherapy
  • 8.4. Corticosteroids
  • 8.5. Immunotherapy
  • 8.6. Monoclonal Antibodies
  • 8.7. Radiation Therapy

9. Castleman Disease Treatment Market, by Application

  • 9.1. Introduction
  • 9.2. Ambulatory Surgical Centers
  • 9.3. Hospitals

10. Americas Castleman Disease Treatment Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Castleman Disease Treatment Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Castleman Disease Treatment Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. FDA Approves Tocilizumab Biosimilar Tofidence
    • 13.3.2. Chugai Obtains Approval for Additional Indication of Actemra for Cytokine Release Syndrome Induced by Cancer Therapy in Japan
    • 13.3.3. Medable Partners with Every Cure to Accelerate Discovery of Treatments for Rare Diseases
  • 13.4. Strategy Analysis & Recommendation

14. Competitive Portfolio

  • 14.1. Key Company Profiles
  • 14.2. Key Product Portfolio

LIST OF FIGURES

  • FIGURE 1. CASTLEMAN DISEASE TREATMENT MARKET RESEARCH PROCESS
  • FIGURE 2. CASTLEMAN DISEASE TREATMENT MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. CASTLEMAN DISEASE TREATMENT MARKET DYNAMICS
  • FIGURE 7. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
  • FIGURE 12. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 14. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. AMERICAS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 16. AMERICAS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. UNITED STATES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 18. UNITED STATES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. ASIA-PACIFIC CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. ASIA-PACIFIC CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 23. CASTLEMAN DISEASE TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 24. CASTLEMAN DISEASE TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. CASTLEMAN DISEASE TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY MULTICENTRIC CASTLEMAN'S DISEASE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY MULTICENTRIC CASTLEMAN'S DISEASE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY UNICENTRIC CASTLEMAN'S DISEASE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY UNICENTRIC CASTLEMAN'S DISEASE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY ANGIOMATOUS LYMPHOID, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY ANGIOMATOUS LYMPHOID, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CASTLEMAN TUMOR, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CASTLEMAN TUMOR, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY GIANT BENIGN LYMPHOMA, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY GIANT BENIGN LYMPHOMA, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY GIANT LYMPH NODE HYPERPLASIA, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY GIANT LYMPH NODE HYPERPLASIA, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY HAMARTOMA OF THE LYPHATICS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY HAMARTOMA OF THE LYPHATICS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 27. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 28. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 29. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY ANTIVIRAL DRUGS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 30. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY ANTIVIRAL DRUGS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 31. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 32. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 33. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 34. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 35. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 36. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 37. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 38. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 39. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY RADIATION THERAPY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 40. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY RADIATION THERAPY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 41. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 42. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 43. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 44. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 45. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 46. GLOBAL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 47. AMERICAS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 48. AMERICAS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 49. AMERICAS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 50. AMERICAS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 51. AMERICAS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 52. AMERICAS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 53. AMERICAS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 54. AMERICAS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 55. AMERICAS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 56. AMERICAS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 57. ARGENTINA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 58. ARGENTINA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 59. ARGENTINA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 60. ARGENTINA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 61. ARGENTINA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 62. ARGENTINA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 63. ARGENTINA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 64. ARGENTINA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 65. BRAZIL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 66. BRAZIL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 67. BRAZIL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 68. BRAZIL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 69. BRAZIL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 70. BRAZIL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 71. BRAZIL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 72. BRAZIL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 73. CANADA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 74. CANADA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 75. CANADA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 76. CANADA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 77. CANADA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 78. CANADA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 79. CANADA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 80. CANADA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 81. MEXICO CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 82. MEXICO CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 83. MEXICO CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 84. MEXICO CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 85. MEXICO CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 86. MEXICO CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 87. MEXICO CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 88. MEXICO CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 89. UNITED STATES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 90. UNITED STATES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 91. UNITED STATES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 92. UNITED STATES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 93. UNITED STATES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 94. UNITED STATES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 95. UNITED STATES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 96. UNITED STATES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 97. UNITED STATES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 98. UNITED STATES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 99. ASIA-PACIFIC CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 100. ASIA-PACIFIC CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 101. ASIA-PACIFIC CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 102. ASIA-PACIFIC CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 104. ASIA-PACIFIC CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 105. ASIA-PACIFIC CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 106. ASIA-PACIFIC CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 107. ASIA-PACIFIC CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 108. ASIA-PACIFIC CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 109. AUSTRALIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 110. AUSTRALIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 111. AUSTRALIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 112. AUSTRALIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 113. AUSTRALIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 114. AUSTRALIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 115. AUSTRALIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 116. AUSTRALIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 117. CHINA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 118. CHINA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 119. CHINA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 120. CHINA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 121. CHINA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 122. CHINA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 123. CHINA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 124. CHINA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 125. INDIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 126. INDIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 127. INDIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 128. INDIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 129. INDIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 130. INDIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 131. INDIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 132. INDIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 133. INDONESIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 134. INDONESIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 135. INDONESIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 136. INDONESIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 137. INDONESIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 138. INDONESIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 139. INDONESIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 140. INDONESIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 141. JAPAN CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 142. JAPAN CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 143. JAPAN CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 144. JAPAN CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 145. JAPAN CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 146. JAPAN CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 147. JAPAN CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 148. JAPAN CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 149. MALAYSIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 150. MALAYSIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 151. MALAYSIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 152. MALAYSIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 153. MALAYSIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 154. MALAYSIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 155. MALAYSIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 156. MALAYSIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 157. PHILIPPINES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 158. PHILIPPINES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 159. PHILIPPINES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 160. PHILIPPINES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 161. PHILIPPINES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 162. PHILIPPINES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 163. PHILIPPINES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 164. PHILIPPINES CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 165. SINGAPORE CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 166. SINGAPORE CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 167. SINGAPORE CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 168. SINGAPORE CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 169. SINGAPORE CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 170. SINGAPORE CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 171. SINGAPORE CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 172. SINGAPORE CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 173. SOUTH KOREA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 174. SOUTH KOREA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 175. SOUTH KOREA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 176. SOUTH KOREA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 177. SOUTH KOREA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 178. SOUTH KOREA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 179. SOUTH KOREA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 180. SOUTH KOREA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 181. TAIWAN CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 182. TAIWAN CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 183. TAIWAN CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 184. TAIWAN CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 185. TAIWAN CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 186. TAIWAN CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 187. TAIWAN CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 188. TAIWAN CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 189. THAILAND CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 190. THAILAND CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 191. THAILAND CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 192. THAILAND CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 193. THAILAND CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 194. THAILAND CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 195. THAILAND CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 196. THAILAND CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 197. VIETNAM CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 198. VIETNAM CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 199. VIETNAM CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 200. VIETNAM CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 201. VIETNAM CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 202. VIETNAM CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 203. VIETNAM CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 204. VIETNAM CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 205. EUROPE, MIDDLE EAST & AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 206. EUROPE, MIDDLE EAST & AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 207. EUROPE, MIDDLE EAST & AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 208. EUROPE, MIDDLE EAST & AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 209. EUROPE, MIDDLE EAST & AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 210. EUROPE, MIDDLE EAST & AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 211. EUROPE, MIDDLE EAST & AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 212. EUROPE, MIDDLE EAST & AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 213. EUROPE, MIDDLE EAST & AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 214. EUROPE, MIDDLE EAST & AFRICA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 215. DENMARK CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 216. DENMARK CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 217. DENMARK CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 218. DENMARK CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 219. DENMARK CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 220. DENMARK CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 221. DENMARK CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 222. DENMARK CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 223. EGYPT CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 224. EGYPT CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 225. EGYPT CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 226. EGYPT CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 227. EGYPT CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 228. EGYPT CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 229. EGYPT CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 230. EGYPT CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 231. FINLAND CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 232. FINLAND CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 233. FINLAND CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 234. FINLAND CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 235. FINLAND CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 236. FINLAND CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 237. FINLAND CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 238. FINLAND CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 239. FRANCE CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 240. FRANCE CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 241. FRANCE CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 242. FRANCE CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 243. FRANCE CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 244. FRANCE CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 245. FRANCE CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 246. FRANCE CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 247. GERMANY CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 248. GERMANY CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 249. GERMANY CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 250. GERMANY CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 251. GERMANY CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 252. GERMANY CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 253. GERMANY CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 254. GERMANY CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 255. ISRAEL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 256. ISRAEL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 257. ISRAEL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 258. ISRAEL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 259. ISRAEL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 260. ISRAEL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 261. ISRAEL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 262. ISRAEL CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 263. ITALY CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 264. ITALY CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 265. ITALY CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 266. ITALY CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 267. ITALY CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 268. ITALY CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 269. ITALY CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 270. ITALY CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 271. NETHERLANDS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 272. NETHERLANDS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 273. NETHERLANDS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 274. NETHERLANDS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 275. NETHERLANDS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 276. NETHERLANDS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 277. NETHERLANDS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 278. NETHERLANDS CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 279. NIGERIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 280. NIGERIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 281. NIGERIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 282. NIGERIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 283. NIGERIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 284. NIGERIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 285. NIGERIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 286. NIGERIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 287. NORWAY CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 288. NORWAY CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 289. NORWAY CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 290. NORWAY CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 291. NORWAY CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 292. NORWAY CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 293. NORWAY CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 294. NORWAY CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 295. POLAND CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 296. POLAND CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 297. POLAND CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 298. POLAND CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 299. POLAND CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 300. POLAND CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 301. POLAND CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 302. POLAND CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 303. QATAR CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 304. QATAR CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 305. QATAR CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 306. QATAR CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 307. QATAR CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 308. QATAR CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 309. QATAR CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 310. QATAR CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 311. RUSSIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 312. RUSSIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 313. RUSSIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 314. RUSSIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 315. RUSSIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 316. RUSSIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 317. RUSSIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 318. RUSSIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 319. SAUDI ARABIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 320. SAUDI ARABIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 321. SAUDI ARABIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 322. SAUDI ARABIA CASTLEMAN DISEASE TREATMENT MARKET SIZE, BY INDI